Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2026 · 64 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glyceroltrinitrat (ATC-Code nach WHO: C05AE01)

50/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

40 / 100

Facteurs de risque

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat (ATC: C05AE01)
  • Open House model: any eligible pharmaceutical entrepreneur can participate
Afficher le résumé complet

Non-exclusive pharmaceutical discount agreements (Rabattvereinbarungen) under §130a(8) SGB V for the active ingredient Glyceroltrinitrat (ATC: C05AE01) via an Open House model. Buyer is AOK PLUS for the regions of Saxony and Thuringia, Germany. The process is open to all eligible pharmaceutical entrepreneurs; no competitive award, all qualified participants are accepted. Contract ends 31 October 2026. Purchase volume and value are unknown. The notice clarifies this is not a public procurement subject to EU procurement law.

Risques

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
  • No connections to Russia per EU sanctions (Regulation 833/2014)

Administrative

  • Complete and submit documents via DTVP portal

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No specific award criteria disclosed; this is a non-competitive Open House model.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat. Open House model: all interested pharmaceutical companies meeting conditions can participate; no individual negotiations; no exclusivity; no minimum purchase quantities; rolling submissions until final deadline.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Oct 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No specific award criteria disclosed; this is a non-competitive Open House model.

Date limite

Deadline Oct 31, 2026

Détails de la procédure

Date de publication
29 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
346931-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30